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In 2012, it was estimated that 9180 people in the United States would die from melanoma and that more than
76,000 new cases would be diagnosed. Surgical resection is effective for early-stage melanoma, but outcomes are
poor for patients with advanced disease. Expression of tumor-associated antigens by melanoma cells makes
the disease a promising candidate for immunotherapy. The hematopoietic cytokine granulocyte–macrophage
colony-stimulating factor (GM-CSF) has a variety of effects on the immune system including activation of T cells and
maturation of dendritic cells, as well as an ability to promote humoral and cell-mediated responses. Given its
immunobiology, there has been interest in strategies incorporating GM-CSF in the treatment of melanoma.
Preclinical studies with GM-CSF have suggested that it has antitumor activity against melanoma and can
enhance the activity of anti-melanoma vaccines. Numerous clinical studies have evaluated recombinant
GM-CSF as a monotherapy, as adjuvant with or without cancer vaccines, or in combination with chemotherapy.
Although there have been suggestions of clinical benefit in some studies, results have been inconsistent. More
recently, novel approaches incorporating GM-CSF in the treatment of melanoma have been evaluated. These
have included oncolytic immunotherapy with the GM-CSF–expressing engineered herpes simplex virus
talimogene laherparepvec and administration of GM-CSF in combination with ipilimumab, both of which
have improved patient outcomes in phase 3 studies. This review describes the diverse body of preclinical
and clinical evidence regarding use of GM-CSF in the treatment of melanoma.
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In 2012, it was estimated that 9180 people in the United
States would die from melanoma and more than 76,000
new cases would be diagnosed [1]. The primary treatment
for melanoma, excision of the malignancy, is highly effect-
ive in early-stage disease but is not a meaningful option
for metastatic disease except in patients with solitary me-
tastases or limited-volume disease [2]. For patients with
advanced disease, cytotoxic chemotherapy has a limited
role and curative potential in <1% of patients. For BRAF-
mutant patients, treatment with vemurafenib, dabrafenib,
and/or tremetinib have high rates of objective response,* Correspondence: howard.kaufman@rutgers.edu
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after which rapid disease progression is common [2].
However, some patients with melanoma respond to im-
munotherapy with durable responses, and thus immuno-
therapy shows substantial promise for further improving
durable control of advanced melanoma.
Expression of tumor-associated antigens by melanoma
cells makes the disease a promising candidate for im-
munotherapy [3]. The potential for immunotherapy in
melanoma has been demonstrated by improved out-
comes among patients with stage III melanoma receiving
interferon-α2b [4] and patients with metastatic melan-
oma receiving the anti-cytotoxic T-lymphocyte antigen 4
(CTLA-4) antibody ipilimumab alone or in combinational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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well as by durable complete responses with high-dose
interleukin-2 [7] and high response rates after adoptive
T cell transfer therapies [8].
The hematopoietic cytokine granulocyte–macrophage
colony-stimulating factor (GM-CSF) has been investi-
gated as a monotherapy, and as a component of combin-
ation therapies for melanoma. Preclinical evidence has
suggested that GM-CSF may have antitumor effects, but
results from clinical trials evaluating GM-CSF present a
complex picture. This review evaluates evidence regard-
ing use of GM-CSF in melanoma and potential future
strategies in this setting.
Review
Immunobiology of GM-CSF
GM-CSF was identified as a factor responsible for expan-
sion and activation of granulocytes and macrophages, but
has since been found to have many direct and indirect ef-
fects on multiple cell types, including cell proliferation,
maturation, and survival (Figure 1A) [9]. GM-CSF plays a
critical role in development and maturation of dendritic
cells (DCs) and proliferation and activation of T cells, link-
ing the innate and acquired immune response [10]. In
mice, increased numbers of eosinophils, monocytes, mac-
rophages, and lymphocytes were observed in the draining
lymph node in response to treatment with irradiated mel-
anoma cells expressing GM-CSF, resulting in a sustained
antitumor response [11]. GM-CSF has also been shown to
favor expansion of DC1 populations [12,13] and to in-
crease DC-mediated responses to tumor cells (Figure 1B)
[14]. In vitro studies using human myeloid leukemia cells
suggest that, in addition to promoting antigen presenta-
tion, GM-CSF directs these cells toward a DC phenotype
[15,16]. The role of GM-CSF in neutrophil proliferation
and survival led to its use in amelioration of neutropenia
following induction chemotherapy in elderly patients with
acute myeloid leukemia [17].
Studies evaluating GM-CSF in preclinical models of
melanoma
The immune adjuvant properties of GM-CSF led to numer-
ous preclinical studies assessing the ability of GM-CSF to
inhibit tumor growth and/or mediate tumor regression. In
a seminal study, a panel of recombinant retroviral vectors
expressing various cytokines, co-stimulatory molecules, or
adhesion molecules were used to infect murine B16 melan-
oma cells. Infected cells were then irradiated and injected
subcutaneously into immune-competent hosts, followed by
a subsequent challenge with wild-type B16 cells [11].
The GM-CSF–secreting tumor vaccines conveyed 90%
protection, whereas vaccines expressing interleukin-2 and
interferon-γ failed to mediate antitumor protection [11].
Additionally, analysis of the vaccination site revealed aninflux of dividing monocytes and granulocytes, with a co-
incident increase in lymphocytes in tumor-draining lymph
nodes, suggesting direct augmentation of antigen presen-
tation and T-cell priming against the tumor [11].
Exogenously administered GM-CSF has been shown to
augment antitumor immunity Mice immunized with an
HIV envelope peptide vaccine plus GM-CSF exhibited in-
creased cytotoxic T lymphocyte (CTL) activity compared
with vaccine alone or vaccine with interleukin-2 [18]. Stud-
ies using a tumor-associated antigen vaccine (neu), in com-
bination with GM-CSF, produced increased neu-specific
antibodies alongside an enhanced CTL response [19,20].
However, tumor protection was ultimately dependent on a
cell-mediated response since depletion of CD8+ T cells ab-
rogated tumor regression.
Genetically modified vaccines can generate protective
anti-melanoma immune responses in animal models [21].
B16 tumor lines expressing bioactive levels of murine
GM-CSF have been generated and assessed [11,21,22].
Levels of GM-CSF at the site of GM-CSF–expressing
tumor transplantation remain elevated for days, whereas
GM-CSF dissipated rapidly after injection of irradiated
tumor with recombinant GM-CSF [22]. The pharmacoki-
netic longevity associated with the vaccine correlated with
both increased DC infiltration and tumor protection
against wild-type tumors [22].
Oncolytic immunotherapy with modified herpes simplex
viruses (HSV) and vaccinia viruses expressing GM-CSF
have also shown promise. These vectors have elicited tumor
responses in mice when injected directly into tumor lesions
[23-25]. In a murine melanoma model, a temperature-
sensitive strain of HSV encoding murine GM-CSF signifi-
cantly reduced Harding-Passey melanoma tumor growth
and improved survival of tumor-bearing mice [25]. Simi-
larly, preclinical studies demonstrated a potent lytic ef-
fect against lesions injected with the GM-CSF–expressing
oncolytic HSV talimogene laherparepvec (T-VEC; formerly
OncovexGM-CSF) [26]. Notably, when virus expressing GM-
CSF was employed, regression of uninjected, distant lesions
was enhanced compared with a regression observed with a
control virus not expressing GM-CSF.
The combination of GM-CSF–secreting tumor vaccines
with other immunotherapies is another potentially promis-
ing approach. Antibodies that block the co-inhibitory T-cell
molecules CTLA-4 and PD-1 plus GM-CSF have boosted
immune responses against melanomas [5,27-31]. Addition-
ally, activation of co-stimulatory molecules (CD80, CD86,
CD137), exogenous cytokine administration (interleukin-2,
interferon-γ), and blockade of tumor angiogenesis can in-
hibit melanoma progression when combined with GM-
CSF–expressing vaccines [32-36]. These preclinical studies
strongly suggest that the combination of GM-CSF–based
tumor vaccines with immunomodulatory agents has poten-
tial for clinical use.
Figure 1 Immunobiologic effects of GM-CSF. (A) Effects of GM-CSF on cells of the immune system. (B) Effects of GM-CSF on dendritic cells
and T cells in the tumor microenvironment.
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GM-CSF in patients with melanoma
Given the evidence of antitumor activity in preclinical
models of melanoma, there has been interest in using
GM-CSF to improve outcomes in the clinical setting.
Numerous studies have evaluated use of recombinant
GM-CSF in completely resected stage III/IV melanoma
patients. Data from these studies, however, have been
inconsistent.
GM-CSF as an adjuvant therapy
GM-CSF has been evaluated as an adjuvant, systemic
monotherapy following regional lymphadenectomy, to
prevent or to delay recurrence in high-risk stage III pa-
tients (Table 1). In a phase 2 study, there were statistically
significant improvements in survival among patients with
stage III/IV disease (P = 0.04 and P < 0.001, respectively)
receiving GM-CSF (125 μg/m2 daily for 14 consecutive
days in 28-day cycles up to 1 year) compared with histor-
ical controls [37]. A subsequent single-arm study using
the same dosing regimen evaluated treatment with GM-
CSF over 3 years and reported a 5-year survival rate of
60%, with 5-year disease-free survival (DFS) of 67% and
40% for patients with stage III and IV disease, respectively
[38]. The effect of GM-CSF on DC has been proposed as
a mechanism for supporting antitumor immunity; consist-
ent with this hypothesis, treatment with recombinant
GM-CSF has increased mature DCs in melanoma pa-
tients [39]. A randomized study of recombinant GM-
CSF (125 μg/m2 daily for 14 consecutive days in 28-day
cycles) versus placebo in patients with completely
resected stage IIIB/IIIC/IV or mucosal melanoma, there
was a trend toward improvement in DFS although it did
not reach statistical significance (11.5 vs 9.2 months; HR,
0.88; P = 0.14), and no improvement in overall survival
(OS; 69.6 vs 62.4 months; HR, 0.96; P = 0.78) [40]. How-
ever, an improvement in DFS (HR, 0.74; P = 0.04) and a
trend toward improved OS (HR, 0.72; P = 0.07) was ob-
served in stage IV patients (n = 258) [40].Table 1 Clinical studies evaluating adjuvant GM-CSF in patien
Citation Evaluable patients GM-CSF dose schedule
Spitler et al. [37] 48 125 μg/m2 for 14 d, 28-d c
Markovic et al. [41] 70 (Stage IV) 149 (Stage III) 125 μg/m2 for 14 d, 28-d c
for 1 y 125 μg/m2 for 14 d
Isla et al. [42] 24 150 mg/d for 2 y
Elias et al. [43] 45 125 μg/m2 for 14 d, then
for 4 d,/28-d cycle, ± auto
Spitler et al. [38] 98 125 μg/m2 for 14 d, 28-d c
Lawson et al. [40] 743 250 μg/m2 for 14 d, 28-d c
DFS = disease-free survival; GM-CSF = granulocyte-macrophage colony-stimulating fGM-CSF as intratumoral monotherapy
Several small studies have evaluated GM-CSF adminis-
tered as a monotherapy by direct injection into meta-
static lesions (Table 2). Clinical responses in two of
these studies were modest, with only one partial re-
sponse (PR) and no complete response (CR) reported
[44,45]. In contrast, a study using perilesional injection
of GM-CSF (400 μg/d over 5 days) to treat metastatic
melanoma described reduced lesion size in 6/7 patients
and a reduction in cutaneous metastases in 5/7 patients
[46]. Three patients were still alive at 5-years follow-up;
a fourth died tumor-free at age 93. In these studies,
there was evidence of increases in DC and T-cell counts
and infiltration at injected sites, and in some cases at
uninjected sites, suggesting an immunologic effect of
GM-CSF injection [44-46]. Other studies using novel
methods (such as aerosolization and immunoemboliza-
tion) to delivering GM-CSF to melanoma metastases at
sites that are not readily injectable have met with mixed
results (Table 2) [47-50].GM-CSF in combination with chemotherapy
A number of early-phase clinical studies have evaluated
GM-CSF in conjunction with chemotherapy (Table 3).
These studies were typically small with a single-arm de-
sign and used a variety of different drug regimens and
dosing schedules; thus, as a whole, they are difficult to
interpret. Clinical efficacy in studies varied widely, with
response rates ranging from no response to >40%
[53-58]. It is worth noting that several of the studies
reporting high overall response rates also reported sig-
nificant increases in T-cell, DC, macrophage, or natural
killer–cell populations following treatment [53,55,58].
One study evaluating a chemotherapy regimen of dacar-
bazine, interferon-α2b, interleukin-2, and tamoxifen with
three doses of GM-CSF reported a dose–response effect
with increasing exposure to GM-CSF via administration
over a greater number of days (P = 0.016) [59].ts with surgically resected melanoma
Control Clinical response
ycles, for 1 y Historical OS: 37.5 mo
ycles,
, 28-d cycles, for 1 y
Observation OS: 6.6 y (GM-CSF) vs 6.8 y (control)
OS: 8.6 (GM-CSF) vs 5.2 y (control)
None DFS at 1 y: 88.8%
IL-2 9 × 106 IU/m2
logous vaccine
None DFS at 15.9 mo: 60% OS at 21 mo:
64% (21 mo follow-up)
ycles, for 3 y None DFS: 1.4 y 5-y survival: 60%
ycles, for 1 y Placebo OS: 62.4 mo for placebo vs.
69.6 mo for GM-CSF (HR, 0.96)
DFS: 9.2 mo for placebo vs. 11.5 mo
for GM-CSF (HR, 0.88)
actor; HR = hazard ratio; IL-2 = interleukin-2; OS = overall survival.
Table 2 Studies evaluating GM-CSF as a monotherapy in patients with advanced melanoma
Citation Evaluable
patients
GM-CSF dose schedule Route of
administration
Clinical response Observations
Si et al. [44] 13 15–50 μg/lesion at 2 sites per patient Intralesional 1 PR, 8 SD Responding patients had increased T-cell and
Langerhans cell infiltration of the tumor
Site 1: 5 times daily
Site 2: 5 times daily then once weekly for 6 mo
Nasi et al. [45] 16 10, 20, 40, or 80 μg/injection for 10 d Intralesional 3 SD Significant increase in DCs and T cells at injection sites
Vaquerano et al. [51] 1 500 μg/d for 4 d, monthly Intralesional 1 PR Regression of melanoma cells
Hoeller et al. [46] 7 400 μg/d for 5 d, 21-d cycle Perilesional 6 with reduced lesion size Increased infiltration of monocytes and lymphocytes
was observed in injected and systemic sites




2 PR, 2 MR, 7 SD Some evidence of systemic immune activation
Rao et al. [47] 14 250 μg twice daily for 7 d on alternating weeks Aerosol delivery for lung
metastases
6 SD Upregulation of cytotoxic T lymphocytes was
observed in peripheral blood
Markovic et al. [48] 35 500–2000 μg (250-μg/dose increments)
twice daily on days 1–7 and 15–21, over 28 d
Aerosol delivery for lung
metastases
1 PR, 5 SD A trend toward increased immune response was
observed with higher doses; MTD was not reached
Sato et al. [49] 31 25–2000 μg every 4 wk Hepatic artery
immunoembolization
2 CR, 8 PR, 10 SD Prolonged PFS correlated with higher GM-CSF doses
Eschelman et al. [50] 52 2000 μg every 4 wk Hepatic artery
immunoembolization
5 PR, 12 SD Trend toward increased OS with GM-CSF;
prolonged OS with GM-CSF in patients with
bulky metastases
CR = complete response; DC = dendritic cell; GM-CSF = granulocyte-macrophage colony-stimulating factor; IL-2 = interleukin-2; MTD =maximum tolerated dose; MR =mixed response; OS = overall survival;





















Table 3 Studies evaluating GM-CSF in combination with chemotherapy in patients with advanced melanoma
Citation Evaluable
patients
GM-CSF dose schedule Other agents Clinical response
Schacter et al. [53] 40 20 μg/m2 once daily for 7 d every 3 wk BCNU, CDDP, DTIC, tamoxifen,
IFN-α
9 CR, 11 PR, 2 SD OS:14 mo
Gajewski et al. [60] 7 5 μg/kg for 6 d DTIC, CDDP, IL-2, IFN-α 1 CR, 1 PR, 2 MR
Gibbs et al. [61] 60 250 μg/m2 for 20 d, 28-d cycle TMZ, CDDP, IL-2, IFN-α 1 CR, 11 PR Median OS: 11 mo
Vaughan et al. [59] 19 Arm 1: 450 μg/m2 on days 4, 5, 15, and 16 DTIC, CDDP, IL-2, IFN-α, TAM 2 CR, 4 PR OS: 6.2 mo Trend toward increasing response
with higher GM-CSF doses
Arm 2: 450 μg/m2 on days 4, 5, 15, 16; 225 μg/m2
on days 6–10 and 17–21, 28-d cycle
Arm 3: 450 μg/m2 on days 4–10 and 15–21, 28-d cycle
Gong et al. [62] 30 5 μg/kg (first 25 patients) or 450 μg/m2
(last 8 patients) for 6 d
DTIC, CDDP, IL-2, IFN-α 3 CR, 4 PR, 6 MR, 7 SD Median OS: 15 mo
Groenewegen et al. [63] 31 2.5 μg/kg for 10 d DTIC, IL-2, IFN-α 4 CR, 6 PR Median OS: 8 mo 1-y survival: 22%
De Gast et al. [64] 74 2.5 μg/kg for 12 d TMZ, IL-2, IFN-α 4 CR, 19 PR, 13 SD OS: 8.3 mo 1-y survival: 41%
Smith et al. [65] 8 125 and 250 μg/m2/d for 7 d every 2 wk, 28-d cycle IL-2 0 CR, 0 PR
Fruehauf et al. [54] 10 250 μg/m2 for 11 d DOX, VIN 0 CR, 5 PR Median time to progression: 8 mo
Lewis et al. [66] 71 250 μg/m2 for 20 d, 28-d cycle TMZ, CDDP, IFN-α, IL-2 0 CR, 10 PR Median OS: 8.6 mo
Weber et al. [67] 31 125 μg/m2 for 12 d, 28-d cycle TMZ, IL-2, IFN-α 4 CR, 4 PR, 7 SD OS: 13.1 mo
Jin et al. [55] 18 175 μg/m2 for 4 d, 21-d cycle DTIC, IL-2 4 CR, 8 PR
O’Day [56] 131 Induction: 500 μg/d for 10 d or once daily until
ANC >5000/μL
Induction: VBL, CDDP, DTIC, IL-2,
IFN-α
10 CR, 47 PR, 38 SD Median OS: 13.5 mo 1-y survival: 57%
Maintenance: 250 μg/d for 14 d Maintenance: IL-2
Gunturu et al. [68] 18 250 μg/m2 from day 8 until AGC >5000 cells/μL on 2
consecutive days
CTX, FLU, MESNA, IL-2 1 CR, 3 PR
Locke et al. [57] 14 250 μg/m2 until WBC >30000/μL or for 10 d, 21-d cycle OX, DOX 0 CR, 0 PR, 5 SD
Lutzky et al. [69] 30 125 μg/m2 for 35 d IL-2 0 CR, 4 PR, 8 SD Median OS: 10.7 mo 1-y survival: 32.5%
AGC = absolute granulocyte count; ANC = absolute neutrophil count; BCNU = carmustine; CDDP = cisplatin; CR = complete response; CTX = cyclophosphamide; DOX = docetaxel; DTIC = dacarbazine; FLU = fludarabine;
GM-CSF = granulocyte-macrophage colony-stimulating factor; IFN-α = interferon-α; IL-2 = interleukin-2; MESNA = sodium 2-mercaptoethanesulfonate; MR =mixed response; OS = overall survival; OX = oxaliplatin;
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Given the significant body of evidence from preclinical
studies [11,18,20,21,70], GM-CSF has been evaluated as
an adjuvant to cancer vaccines in a number of clinical
studies. Several approaches to administering GM-CSF as
an adjuvant have been employed, including coadminis-
tration with the vaccine [71-74], injection at the vaccin-
ation site [75,76] systemic administration [77,78], and
administration of a plasmid/viral vector encoding GM-
CSF [79,80]. The dose of GM-CSF administered as an
adjuvant is typically less than the recommended overall
weekly dose of 250 μg/m2/day for 21 days for use in
myeloid reconstitution after autologous bone marrow
transplantation [17].
In contrast to data from murine studies, the adjuvant
effect of GM-CSF in human trials is inconsistent. In a
study that evaluated coadministration of GM-CSF with
multipeptide (including gp100 and tyrosinase peptides)
melanoma vaccines incorporating GM-CSF and incom-
plete Freund’s adjuvant (IFA) in patients with advanced
melanoma, there was a high T-cell response rate and a
correlation between T-cell reactivity to the melanoma
peptides and clinical outcome [72]. GM-CSF combined
with IFA as an adjuvant for a vaccine containing 12 melan-
oma peptides resulted in a similar immunologic response
in patients with resected stage III/IIIB/IV melanoma [74].
Similarly, systemic administration of GM-CSF following a
peptide vaccination augmented T-cell response in three pa-
tients with advanced melanoma [77]. However, in a study
that evaluated intradermal vaccination with tyrosinase pep-
tides followed by intradermal GM-CSF, detectable T-cell
responses were observed in only 4/15 (27%) evaluable pa-
tients [76].
Although results from these studies have suggested that
administration of adjuvant GM-CSF might improve im-
mune responses, none included control groups. Recently,
clinical trials including controls have evaluated effects of
GM-CSF administered locally at the vaccination site
(Table 4). In a phase 1 study comparing different adjuvant
strategies, vaccination with tyrosinase peptide plus GM-
CSF or keyhole limpet hemocyanin (KLH) did not induce
greater immune responses compared with vaccination
with peptide alone, although combination with GM-CSF
plus KLH had a moderate adjuvant effect [75]. Two recent
randomized prospective trials suggested that addition of
GM-CSF to melanoma vaccines did not improve cellular
immune responses and, indeed, may have had negative ef-
fects [71,81]. Notably, both studies combined GM-CSF
with another adjuvant (IFA or BCG) which may have in-
fluenced the immune response. The inconsistent effect of
GM-CSF on immune responses to vaccines may be due in
part to competing effects inducing dendritic cell matur-
ation on one hand, and inducing myeloid suppressor cells
on the other. A recent phase 2, randomized controlledtrial (E1696) evaluated treatment of advanced melanoma
with multipeptide vaccine alone or with subcutaneous
interferon-α, GM-CSF, or interferon-α plus GM-CSF
[78,82]. Consistent with results of studies evaluating ad-
ministration of GM-CSF at the vaccine site, no significant
improvement in T-cell or clinical response was observed
with interferon-α and/or GM-CSF administration with
vaccination [78,82].
Results from clinical studies evaluating GM-CSF as an
adjuvant to melanoma vaccines suggest the biologic effects
of GM-CSF are complex and can be influenced by numer-
ous factors. GM-CSF administered with a heat shock pro-
tein vaccine has been implicated in the induction of
myeloid-derived suppressor cells (MDSC) in melanoma
patients [83]. On the other hand, daily subcutaneous ad-
ministration of GM-CSF (125 μg/m2 for 14 days in 28-day
cycles) increased circulating mature DC but did not in-
crease MDSC in melanoma patients [39]. It has been sug-
gested that negative immunologic effects of GM-CSF may
be associated primarily with high doses of GM-CSF (doses
of 225 μg/d or higher in melanoma patients) [84]. In a
trial of a multipeptide melanoma vaccine, immune re-
sponses were lower with GMCSF plus IFA than with
IFA alone (the dose used in that trial was arguably less
than 20 μg/day) [81]. Thus, even low doses of GM-CSF
administered with a multipeptide vaccine may have
negative immunologic effects. Additional studies are
also needed to determine if GM-CSF alters the function
of vaccine-induced T cells and whether inclusion of
GM-CSF with the vaccine may affect clinical outcome.
Novel strategies incorporating GM-CSF
GM-CSF–expressing oncolytic immunotherapy
Preclinical studies have indicated an important role for
GM-CSF in the tumor microenvironment and have sug-
gested that increased expression of GM-CSF can inhibit
tumor growth. However, administration of exogenous re-
combinant GM-CSF appears insufficient to mediate clin-
ically meaningful improvements in outcomes in most
instances. Consequently, there has been significant inter-
est in novel treatment approaches incorporating GM-
CSF.
Among the most extensively evaluated agents is the atten-
uated, oncolytic, herpes simplex virus, type 1 (HSV-1)–en-
coding human GM-CSF talimogene laherparepvec (T-VEC;
formerly OncovexGM-CSF) [85-88]. The vector was generated
from the HSV JS1 strain and was attenuated by functional
deletion of the ICP34.5 and ICP47 viral genes, which ren-
ders the virus nonpathogenic in normal eukaryotic cells,
promotes selective replication in tumor cells, and enhances
immunogenicity [26] T-VEC has also been engineered to
encode human GM-CSF, which further enhances the antitu-
mor immune response. T-VEC is proposed to have a dual
mechanism of action resulting in local tumor destruction by
Table 4 Cancer vaccines testing the adjuvant effect of GM-CSF administered locally at the site of vaccination
Citation Design
(Enrollment)
Ag (Route) GM-CSF form (Route) Coadmin-
istration?
Study design Effect of GM-CSF Summary
effect of
GM-CSF






75 μg/d x 4 d/vaccine




2. Peptides + GM-CSF
3. Peptides + KLH
4. Peptides + GM-CSF + KLH






Yes Randomized: Negative on CD4 and CD8 T cells;




1. Peptides + IFA
2. Peptides + IFA + GM-CSF




Protein 200 μg/m2/d x 5
days (ID)
Yes Randomized: Better Ab, worse DTH; more Eos,
Dec monocytes; more deaths
Diminished compared
with BCG
1. Whole cell vaccine + BCG
+ GM-CSF
2. Whole cell vaccine + BCG





250 μg/d x 14 out
of 28 days
Yes 2 × 2: No effect across treatment arms
on best overall response
Minimal adjuvant effect
Arm A: Peptide Vaccine
Alone
Arm B: GM-CSF (250 μg/d x
14 out of 28 d) + vaccine
Arm C: IFN-α + vaccine
Arm D: GM-CSF + IFN-α +
vaccine
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duction of a systemic antitumor immune response.
In a phase 1 study, patients with subcutaneous or cu-
taneous metastases from breast, gastrointestinal, head
and neck, or melanoma malignancies were treated with
T-VEC. Clinically stable disease was noted in 3/26 pa-
tients administered intralesional T-VEC, with no pa-
tients having CR or PR during the study period [86].
However, follow-up biopsies in 14/19 patients showed
necrosis, infiltration of T cells, and the presence of repli-
cating virus [86]. Notably, there was evidence of expres-
sion of GM-CSF in injected lesions. In a subsequent
phase 2 study among 50 patients with unresectable stage
IIIC/IV melanoma administered intralesional T-VEC,
the overall response rate was 26% (8 CR, 5 PR) [88].
Two additional patients were rendered disease-free by
surgical resection following treatment. One-year survival
was 58% for all patients and 40% among patients with
stage IVM1c disease. Immunologic analysis of a subset
of patients enrolled in the phase 2 study confirmed the
presence of both local and distant antitumor immune re-
sponses following T-VEC administration. Biopsies per-
formed on 11 patients after their sixth intratumoral
injection were compared to nonstudy patients with
metastatic melanoma [87]. In general, postvaccination
tumors demonstrated extensive lymphocyte infiltration.
Evaluation of both injected and noninjected lesions in
T-VEC–treated patients revealed a significant increase
in MART-1–specific T-cell response in both tumor and
distant disease sites compared with unvaccinated con-
trols. Regulatory CD4+FoxP3+ and suppressor CD8+FoxP3+
T cells and myeloid-derived suppressor cells were evalu-
ated in injected tumor biopsies and found to be decreased
when compared to unvaccinated control patients. When
primary injected lesions were compared to distant nonin-
jected lesions, the same general phenotypic pattern of
effector T-cell and Treg infiltrates was seen; a greater num-
ber of CD4+FoxP3+ and CD8+FoxP3+ cells were present
at the nontarget site than at the target sites. A randomized,
phase 3 study, OPTiM, comparing intralesional T-VEC to
subcutaneous GM-CSF demonstrated an improvement in
durable response rate (16% vs 2%, respectively) and a trend
toward improved OS at interim analysis (HR, 0.79 [95% CI,
0.61–1.02]) favoring the T-VEC arm [89]. The most fre-
quently occurring adverse events were fatigue, chills, and
pyrexia [89].
Systemic combination immunotherapy
GM-CSF has also been combined with ipilimumab, an
anti-CTLA-4 monoclonal antibody. In a multicenter,
phase 2 study, patients with metastatic melanoma were
randomized to treatment with ipilimumab plus GM-CSF
(250 μg/d subcutaneously for 14 days in 21-day cycles)
or ipilimumab alone [90]. Patients receiving combinationtherapy experienced a significant improvement in 1-year
OS. Although there were no significant differences in
overall toxicity between the treatment arms, patients re-
ceiving combination therapy had a lower rate of serious
adverse events.
Several other approaches utilizing GM-CSF are being
developed. These include an oncolytic vaccinia virus en-
coding GM-CSF [91], autologous dendritic cells and
allogeneic whole tumor cells encoding GM-CSF [92-94],
adjuvant GM-CSF following vaccination with peptide or
RNA encoding melanoma peptides [95,96] and autolo-
gous dendritic cell or whole tumor cell vaccines [97],
and GM-CSF DNA vaccines [98].
Conclusions
GM-CSF has been studied extensively in murine models
and in human clinical trials, alone and as adjuvant ther-
apy for melanoma. There is evidence from numerous
studies that GM-CSF can induce antitumor immunity
when administered by a variety of different routes. Al-
though there was initial enthusiasm for recombinant
GM-CSF based on uncontrolled clinical trials in stage
III/IV melanoma, therapeutic benefit has not been con-
firmed in larger, prospective, randomized trials. The ad-
juvant or combination use of GM-CSF has been more
promising although results have been inconsistent and
may depend on the potency of the immunotherapy regi-
men, GM-CSF dose, route and schedule of administra-
tion, and stage of disease. There is emerging evidence
that GM-CSF may be a regulatory cytokine with the ability
to promote both effector and regulatory/suppressor T cell
populations. Thus, strategies that block suppressor T cell
and myeloid-derived suppressor cell elements may en-
hance the antitumor activity of GM-CSF. GM-CSF has
been particularly effective in studies of oncolytic HSV
therapy of melanoma and in combination with ipilimu-
mab. Further research into the basic biology of GM-CSF
on effector and suppressor immune cells and expanded
clinical studies of combination treatments will help define
the full therapeutic potential of GM-CSF in treatment of
melanoma.
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